` CBD (Cannabis Poland SA) vs WIG20 Comparison - Alpha Spread

C
CBD
vs
W
WIG20

Over the past 12 months, CBD has underperformed WIG20, delivering a return of -50% compared to the WIG20's +36% growth.

Stocks Performance
CBD vs WIG20

Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
CBD vs WIG20

Performance Gap Between CBD and WIG20
HIDDEN
Show

Performance By Year
CBD vs WIG20

Loading
CBD
WIG20
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Cannabis Poland SA vs Peers

No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Cannabis Poland SA
Glance View

Market Cap
13.8m PLN
Industry
Pharmaceuticals

Cannabis Poland SA engages in the production and distribution of cannabinoid vaporization equipment and oils. The company is headquartered in Warsaw, Woj. Mazowieckie. The company went IPO on 2013-04-09. The firm focuses on operating in the field of production and sale of pharmaceutical and medical products, with the main focus on vaporization products containing cannabinoids manufactured from cannabis. The firm also expands its activity to include other products than pharmaceuticals, such as cosmetics, oils containing cannabinoids for human and animals and photovoltaic cells. The firm is engaged in research and development of a Cannabidiol (CBD)/ Tetrahydrocannabinol-based (THC-based) pharmaceutical for use in the treatment of seizures associated with drug-resistant epilepsy.

CBD Intrinsic Value
HIDDEN
Show
Back to Top